マルチモーダルImaging-とてんかんの患者で接続関連の脳の興奮性を評価するの刺激に基づく方法

Executive Industry Relevance

This multimodal imaging and stimulation method enables biopharma R&D to assess cortical hyperexcitability in epilepsy models, supporting target validation by linking functional connectivity abnormalities to electrophysiological phenotypes. It provides a mechanistic de-risking tool for evaluating circuit-level excitability changes in preclinical and translational studies, particularly for neuropsychiatric indications where network hyperexcitability is a putative driver of disease. The approach enhances predictive confidence in target selection by demonstrating causal relevance of connectivity alterations to pathophysiological states.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses by testing whether regions with abnormal resting-state connectivity exhibit causal hyperexcitability via TMS-EEG perturbation.
• Operational Value: Enables biological de-risking of targets by establishing whether connectivity changes correlate with measurable electrophysiological dysfunction in disease-relevant systems.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems with quantified TMS-evoked EEG responses as a standardized assay for screening compounds that modulate cortical excitability.
• Operational Value: Supports assay reproducibility through MRI-guided targeting and ICA-based artifact removal, enabling reliable longitudinal or cross-condition comparisons.

Translational & Preclinical Research

• Scientific Value: Demonstrates disease relevance by showing that abnormal TMS-evoked activity co-localizes with seizure-onset zones, supporting continuity from connectivity biomarkers to pathophysiological circuits.
• Operational Value: Facilitates risk-adjusted advancement decisions by providing a translatable readout of circuit hyperexcitability that can be monitored across discovery to preclinical stages.

Pipeline & Workflow Integration

The method integrates into the discovery continuum by first identifying aberrant networks via rs-fcMRI, then probing their causal excitability using TMS-EEG, and finally validating target engagement through normalization of abnormal late components in evoked potentials.

• Discovery Biology: Supports hypothesis testing by determining whether functionally connected regions exhibit pathogenic hyperexcitability, clarifying network-level mechanisms in epilepsy models.
• Screening: Enables assay readiness through standardized TMS pulse application and ERP quantification, allowing assessment of compound effects on cortical reactivity.
• Analytics: Generates quantitative dependent variable measurements (e.g., latency and amplitude of late TMS-evoked potential components) that enable statistical comparison between disease and control states.
• Translational Research: Connects to preclinical continuity by demonstrating spatial colocalization of abnormal TMS-evoked activity with epileptogenic zones, supporting biomarker-aligned target validation.
• Enterprise Reuse: Represents a reusable platform for probing circuit excitability across neuropsychiatric indications, not limited to single-use experimental validation.

Operational & Enterprise Impact

• Scientific Value: Provides predictive confidence in target validation by linking connectivity abnormalities to causal electrophysiological phenotypes, reducing mechanistic ambiguity in neuropsychiatric target selection.
• Operational Value: Ensures standardization and reproducibility through neuronavigation-guided TMS, fixed inter-pulse intervals, and multi-stage ICA artifact correction.
• Strategic Value: Improves go/no-go decisions by enabling early detection of circuit hyperexcitability, even when routine EEG is normal, thereby reducing late-stage biological risk in CNS programs.
• Portfolio Impact: Supports risk-adjusted prioritization by identifying targets whose modulation normalizes pathological excitability, informing capital allocation toward mechanistically de-risked candidates.

Implementation Considerations

• Requires expertise in neurophysiology, TMS safety protocols, EEG acquisition, and multimodal image coregistration.
• Depends on neuronavigation systems, TMS coils compatible with simultaneous EEG, and high-density EEG caps to minimize artifacts.
• Necessitates cross-team standardization between imaging, stimulation, and electrophysiology teams to ensure consistent target selection and data interpretation.
• Involves adaptation considerations when applying to different model systems, as head size, coil positioning, and ICA parameters may require optimization across species or strain.
• Includes practical limitations such as susceptibility to movement artifacts, inter-individual variability in skull conductivity, and the need for careful subject screening to exclude contraindications to TMS.

Biopharma FAQs